Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative Gefitinib for Stage II-IIIa NSCLC
NCT01833572Phase 2Completed
- Sponsor
- Fudan University
- Start
- May 2013
- Primary completion
- Oct 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gefitinib in non-small cell lung cancer (NSCLC), sponsored by Fudan University. Primary endpoint: Objective Response Rate at 42 days. Started May 2013; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01833572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01833572.